Implementation of a discontinuation letter to reduce long-term benzodiazepine use-A cluster randomized trial

Drug and Alcohol Dependence

Volumn 99, Issue 1-3, 2009, Pages 105-114

  van de Steeg van Gompel, Caroline H P A ^a   Wensing, Michel ^a   De Smet, Peter A G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Benzodiazepines; Community pharmacy services; General practice; Implementation

Indexed keywords

BENZODIAZEPINE;

AGED; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTCOME ASSESSMENT; PHARMACY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BENZODIAZEPINES; COMMUNITY PHARMACY SERVICES; FAMILY PRACTICE; FOLLOW-UP STUDIES; HUMANS; NETHERLANDS; PATIENT EDUCATION AS TOPIC; PHARMACIES; PHARMACISTS; RANDOM ALLOCATION; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 57049144795     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.07.009     Document Type: Article

References (42)

1. Benrimoj S.I., and Roberts A.S. Providing patient care in community pharmacies in Australia. Ann. Pharmacother. 39 (2005) 1911-1917
2. Berenguer B., La C.C., de la Matta M.J., and Martin-Calero M.J. Pharmaceutical care: past, present and future. Curr. Pharm. Des. 10 (2004) 3931-3946
3. Booij, A., Essink, R., Cambach, W., 2007. Kwaliteitsindicatoren van het FTO. http://www.medicijngebruik.nl/downloads/FTO_kwaliteitsindicatoren_20071123s.pdf. Accessed on November 2007.
4. Christensen D.B., and Farris K.B. Pharmaceutical care in community pharmacies: practice and research in the US. Ann. Pharmacother. 40 (2006) 1400-1406
5. Cormack M.A., Sweeney K.G., Hughes-Jones H., and Foot G.A. Evaluation of an easy, cost-effective strategy for cutting benzodiazepine use in general practice. Br. J. Gen. Pract. 44 (1994) 5-8
6. Cumming R.G., and Le Couteur D.G. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 17 (2003) 825-837
7. de Vries M.A.J. Beter benzodiazepinebeleid. Pharmaceutisch Weekblad 142 (2007) 1818
8. Dunlop J.A., and Shaw J.P. Community pharmacists' perspectives on pharmaceutical care implementation in New Zealand. Pharm. World Sci. 24 (2002) 224-230
9. Ellis B.C., Dovey S.M., Collins D.M., Tilyard M.W., and Clark D.W. General practitioners' views on the role of the community pharmacist. N. Z. Med. J. 105 (1992) 403-405
10. Foundation for Pharmaceutical Statistics (SFK). Ouderen gebruiken minder benzodiazepinen. Pharmaceutisch Weekblad 142 (2007) 13
11. Furukawa T.A., Streiner D.L., and Young L.T. Antidepressant and benzodiazepine for major depression. Cochrane Database Syst. Rev. (2002) (CD001026)
12. Gorgels W.J., Oude Voshaar R.C., Mol A.J., van de Lisdonk E.H., van Balkom A.J., van den Hoogen H.J., Mulder J., Breteler M.H., and Zitman F.G. Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: a prospective controlled intervention study. Drug Alcohol Depend. 78 (2005) 49-56
13. Grimshaw J.M., Thomas R.E., MacLennan G., Fraser C., Ramsay C.R., Vale L., Whitty P., Eccles M.P., Matowe L., Shirran L., Wensing M., Dijkstra R., and Donaldson C. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol. Assess. 8 (2004) iii-72
14. Grol R., Bosch M., and Wensing M. Ontwikkeling of selectie van strategieën voor verandering. In: Grol R., and Wensing M. (Eds). Implementatie. Effectieve verbetering van de patiëntenzorg (2006), Elsevier gezondheidszorg, Maarssen 223-244
15. Health Services Research Unit, U.o.A., Empirical estimates of ICCs from changing professional practice studies. http://www.abdn.ac.uk/hsru/epp/iccs-web.xls. Accessed on April 2005.
16. Hemmelgarn B., Suissa S., Huang A., Boivin J.F., and Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 278 (1997) 27-31
17. Hepler C.D., and Strand L.M. Opportunities and responsibilities in pharmaceutical care. Am. J. Hosp. Pharm. 47 (1990) 533-543
18. Herings R.M., Stricker B.H., de Boer A., Bakker A., and Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 155 (1995) 1801-1807
19. Hofmann A. Wild vuur wordt waakvlam. Pharmaceutisch Weekblad 139 (2004) 1708-1709
20. Hughes C.M., and McCann S. Perceived interprofessional barriers between community pharmacists and general practitioners: a qualitative assessment. Br. J. Gen. Pract. 53 (2003) 600-606
21. Hulscher M.E., Wensing M., van der W.T., and Grol R. Interventions to implement prevention in primary care. Cochrane Database Syst. Rev. (2001) (CD000362)
22. Huyghebaert T., Farris K.B., and Volume C.I. Implementing pharmaceutical care: insights from Alberta community pharmacists. Can. Pharma. J. (La Revue Pharmaceutique Canadienne) 132 (1999) 41-45
23. Jones E.J., Mackinnon N.J., and Tsuyuki R.T. Pharmaceutical care in community pharmacies: practice and research in Canada. Ann. Pharmacother. 39 (2005) 1527-1533
24. Killip S., Mahfoud Z., and Pearce K. What is an intracluster correlation coefficient? Crucial concepts for primary care researchers. Ann. Fam. Med. 2 (2004) 204-208
25. Lader M.H. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?. Eur. Neuropsychopharmacol. 9 Suppl 6 (1999) S399-S405
26. Martin-Calero M.J., Machuca M., Murillo M.D., Cansino J., Gastelurrutia M.A., and Faus M.J. Structural process and implementation programs of pharmaceutical care in different countries. Curr. Pharm. Des. 10 (2004) 3969-3985
27. Morgan J.D., Wright D.J., and Chrystyn H. Pharmacoeconomic evaluation of a patient education letter aimed at reducing long-term prescribing of benzodiazepines. Pharm. World Sci. 24 (2002) 231-235
28. Muijrers P.E., Knottnerus J.A., Sijbrandij J., Janknegt R., and Grol R.P. Changing relationships: attitudes and opinions of general practitioners and pharmacists regarding the role of the community pharmacist. Pharm. World Sci. 25 (2003) 235-241
29. Muijrers P.E., Knottnerus J.A., Sijbrandij J., Janknegt R., and Grol R.P. Pharmacists in primary care. Determinants of the care-providing function of Dutch community pharmacists in primary care. Pharm. World Sci. 26 (2004) 256-262
30. Nathan A., and Sutters C.A. A comparison of community pharmacists' and general practitioners' opinions on rational prescribing, formularies and other prescribing related issues. J. R. Soc. Health 113 (1993) 302-307
31. Niessen W.J., Stewart R.E., Broer J., and Haaijer-Ruskamp F.M. Reduction in the consumption of benzodiazepines due to a letter to chronic users from their own general practitioner. Ned. Tijdschr. Geneeskd. 149 (2005) 356-361
32. Petrovic M., Mariman A., Warie H., Afschrift M., and Pevernagie D. Is there a rationale for prescription of benzodiazepines in the elderly? Review of the literature. Acta Clin. Belg. 58 (2003) 27-36
33. Schneeweiss S., and Wang P.S. Claims data studies of sedative-hypnotics and hip fractures in older people: exploring residual confounding using survey information. J. Am. Geriatr. Soc. 53 (2005) 948-954
34. Sellors J., Kaczorowski J., Sellors C., Dolovich L., Woodward C., Willan A., Goeree R., Cosby R., Trim K., Sebaldt R., Howard M., Hardcastle L., and Poston J. A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ 169 (2003) 17-22
35. Shaw B., Cheater F., Baker R., Gillies C., Hearnshaw H., Flottorp S., and Robertson N. Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. Cochrane Database Syst. Rev. (2005) CD005470
36. Spencer J.A., and Edwards C. Pharmacy beyond the dispensary: general practitioners' views. BMJ 304 (1992) 1670-1672
37. Stewart S.A. The effects of benzodiazepines on cognition. J. Clin. Psychiatry 66 suppl. 2 (2005) 9-13
38. Thomas R.E. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can. Fam. Physician 44 (1998) 799-808
39. Tully M.P., Seston E.M., and Cantrill J.A. Motivators and barriers to the implementation of pharmacist-run prescription monitoring and review services in two settings. Int. J. Pharm. Pract. 8 (2000) 188-197
40. van der Aalst, A., Eimers, M., Westerhuis, G., 2006. FTO-peiling. http://www.medicijngebruik.nl/downloads/FTO-peiling_2006_20070905s.pdf. Accessed on Aug. 2007.
41. van Mil J.W., Schulz M., and Tromp T.F. Pharmaceutical care, European developments in concepts, implementation, teaching, and research: a review. Pharm. World Sci. 26 (2004) 303-311
42. WHO Collaborating Centre for Drug Statistics Methodology, Complete ATC Index. http://www.whocc.no/atcddd/. Accessed on July 2005.